Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Menorrhagia 7Leiomyoma 7Polycystic Ovary Syndrome 1

Interventions

Metformin 14Clomiphene 6Progesterone 5Chorionic Gonadotropin 5drospirenone and ethinyl estradiol combination 4Sugars 4Letrozole 4Flutamide 4Estrogens 4Cholecalciferol 4follitropin alfa 3Pioglitazone 3Medroxyprogesterone Acetate 3Glycoprotein Hormones, alpha Subunit 3Estradiol 3Vitamin D 2Testosterone 2Resistance Training 2Raloxifene Hydrochloride 2Ovidrel 2Liraglutide 2Leuprolide 2Glucose Tolerance Test 2Exenatide 2Ethinyl Estradiol 2Contraceptives, Oral 2Continuous Positive Airway Pressure 2saxagliptin 1salicylsalicylic acid 1penclomedine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Polycystic Ovary Syndrome × elagolix × Clear all
NCT03951077 2022-06-08

Study of the Safety and Efficacy of Elagolix in Women With Polycystic Ovary Syndrome

AbbVie

Phase 2 Completed
118 enrolled 13 charts

Polycystic Ovary Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡